Intranasal administration of a Pseudomonas lipopolysaccharide vaccine in cystic fibrosis patients.
A purified lipopolysaccharide Pseudomonas aeruginosa vaccine was administered via intranasal spray to cystic fibrosis patients in an attempt to induce development of local antibody without the side effects associated with parenteral administration of the vaccine. Although slight increases in serum antibody titers were noted, there was no appreciable change in specific antibody levels in parotid saliva or sputum following intranasal administration of the vaccine.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D003550:Cystic Fibrosis / Q000276:immunology*; D006386:Hemagglutination Tests; D006801:Humans; D008070:Lipopolysaccharides / Q000276:immunology*; D010306:Parotid Gland; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D012463:Saliva / Q000276:immunology; D013183:Sputum / Q000276:immunology
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D008070:Lipopolysaccharides